Society of Interventional Radiology Names Robert J Lewandowski, MD, FSIR, President for 2024–2025

Dr. Robert J Lewandowski

Robert J. Lewandowski, MD, FSIR, an interventional radiologist and professor at Northwestern Medicine Feinberg School of Medicine, Chicago, assumed the office of president of the Society of Interventional Radiology (SIR) on March 26 during the SIR 2024 Annual Scientific Meeting in Salt Lake City.

“Throughout the last 50 years, SIR has enabled the specialty to grow in an evolving healthcare landscape, providing IRs with the education, resources, and support required for members to thrive,” said Lewandowski. “As we look forward, SIR remains committed to fostering healthcare innovations that improve patients’ lives worldwide.”

Other incoming officers of SIR’s 2024–2025 Board of Directors include President-elect Robert A. Lookstein, MD, FSIR, Mount Sinai Health System and Icahn School of Medicine at Mount Sinai, New York; newly appointed Secretary Saher S. Sabri, MD, FSIR, MedStar Georgetown University Hospital; and Immediate Past-president Alda L. Tam, MD, MBA, FSIR, The University of Texas MD Anderson Cancer Center, Houston.

Other appointed and elected SIR leadership positions filled this year are:

SIR Board of Directors

  • Kelvin Hong, MD, FSIR—Director, at-large
  • Nishita Kothary, MD, FSIR—Director, at-large

SIR and SIR Foundation Steering Council

Divisions

  • Sun-Ho Ahn, MD, FSIR—Education Division Councilor
  • Paula Novelli, MD, FSIR—2024–2030 Annual Meeting Program Committee

Clinical Specialty Councils

  • Joseph J. Gemmete, MD, FSIR—Neurointerventional Radiology Council Vice Chair
  • Gulraiz Chaudry, MD, FSIR—Pediatric IR Vice Chair
  • Andrew Gunn, MD, FSIR—Renal and GU Council Vice Chair

SIR Foundation also appointed the following members to its Board of Directors:

  • Clifford R. Weiss, MD, FSIR—Vice Chair
  • Shellie C. Josephs, MD, FSIR—Secretary
  • Nadine Abi-Jaoudeh, MD, FSIR—Clinical Trials and Registries Division Chair
  • Amy C. Taylor, MD—Development Division Chair
  • Dania Daye, MD, PhD—Research Education and Outreach Division Chair

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version